Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
0
조회
0
다운로드
0
인용
0
참고문헌
초록
High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological malignancy. To date, the profiles of gene mutations and copy number alterations in HGSOC have been well characterized. However, the patterns of epigenetic alterations and transcription factor dysregulation in HGSOC have not yet been fully elucidated. In this study, we performed integrative omics analyses of a series of stepwise HGSOC model cells originating from human fallopian tube secretory epithelial cells (HFTSECs) to investigate early epigenetic alterations in HGSOC tumorigenesis. Assay for transposase-accessible chromatin using sequencing (ATAC-seq), chromatin immunoprecipitation sequencing (ChIP-seq), and RNA sequencing (RNA-seq) methods were used to analyze HGSOC samples. Additionally, protein expression changes in target genes were confirmed using normal HFTSECs, serous tubal intraepithelial carcinomas (STICs), and HGSOC tissues. Transcription factor motif analysis revealed that the DNA-binding activity of the AP-1 complex and GATA family proteins was dysregulated during early tumorigenesis. The protein expression levels of JUN and FOSL2 were increased, and those of GATA6 and DAB2 were decreased in STIC lesions, which were associated with epithelial-mesenchymal transition (EMT) and proteasome downregulation. The genomic region around the FRA16D site, containing a cadherin cluster region, was epigenetically suppressed by oncogenic signaling. Proteasome inhibition caused the upregulation of chemokine genes, which may facilitate immune evasion during HGSOC tumorigenesis. Importantly, MEK inhibitor treatment reversed these oncogenic alterations, indicating its clinical effectiveness in a subgroup of patients with HGSOC. This result suggests that MEK inhibitor therapy may be an effective treatment option for chemotherapy-resistant HGSOC.
Abstract
High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological malignancy. To date, the profiles of gene mutations and copy number alterations in HGSOC have been well characterized. However, the patterns of epigenetic alterations and transcription factor dysregulation in HGSOC have not yet been fully elucidated. In this study, we performed integrative omics analyses of a series of stepwise HGSOC model cells originating from human fallopian tube secretory epithelial cells (HFTSECs) to investigate early epigenetic alterations in HGSOC tumorigenesis. Assay for transposase-accessible chromatin using sequencing (ATAC-seq), chromatin immunoprecipitation sequencing (ChIP-seq), and RNA sequencing (RNA-seq) methods were used to analyze HGSOC samples. Additionally, protein expression changes in target genes were confirmed using normal HFTSECs, serous tubal intraepithelial carcinomas (STICs), and HGSOC tissues. Transcription factor motif analysis revealed that the DNA-binding activity of the AP-1 complex and GATA family proteins was dysregulated during early tumorigenesis. The protein expression levels of JUN and FOSL2 were increased, and those of GATA6 and DAB2 were decreased in STIC lesions, which were associated with epithelial-mesenchymal transition (EMT) and proteasome downregulation. The genomic region around the FRA16D site, containing a cadherin cluster region, was epigenetically suppressed by oncogenic signaling. Proteasome inhibition caused the upregulation of chemokine genes, which may facilitate immune evasion during HGSOC tumorigenesis. Importantly, MEK inhibitor treatment reversed these oncogenic alterations, indicating its clinical effectiveness in a subgroup of patients with HGSOC. This result suggests that MEK inhibitor therapy may be an effective treatment option for chemotherapy-resistant HGSOC.
참고문헌 (51)
- Consortium, I. T. P.-C. A. o. W. G., "Pan-cancer analysis of whole genomes", Nature, 578, pp.82~93 (2020)
- Asada, K., "Integrated Analysis of Whole Genome and Epigenome Data Using Machine Learning Technology : Toward the Establishment of Precision Oncology", Front Oncol, 11, pp.666937~ (2021)
- Corces, M. R., "The chromatin accessibility landscape of primary human cancers", Science, 362 (2018)[DOI]
- Cusanovich, D. A., "A Single-Cell Atlas of In Vivo Mammalian Chromatin Accessibility", Cell, 174, pp.1309~1324 (2018)
- Consortium, E. P., "Expanded encyclopaedias of DNA elements in the human and mouse genomes", Nature, 583, pp.699~710 (2020)
- Polak, P., "Cell-of-origin chromatin organization shapes the mutational landscape of cancer", Nature, 518, pp.360~364 (2015)
- Hoadley, K. A., "Cell-of-Origin Patterns Dominate the Molecular Classification of 10, 000 Tumors from 33 Types of Cancer", Cell, 173, pp.291~304 (2018)
- Cancer Genome Atlas Research, N., "Integrated genomic analyses of ovarian carcinoma", Nature, 474, pp.609~615 (2011)
- Lee, Y., "A candidate precursor to serous carcinoma that originates in the distal fallopian tube", J. Pathol, 211, pp.26~35 (2007)
- Kindelberger, D. W., "Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma : Evidence for a causal relationship", Am. J. Surg. Pathol, 31, pp.161~169 (2007)
- Nakamura, K., "Reconstitution of high-grade serous ovarian carcinoma from primary fallopian tube secretory epithelial cells", Oncotarget, 9, pp.12609~12619 (2018)
- Ledermann, J., "Olaparib maintenance therapy in patients with platinumsensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial", Lancet Oncol, 15, pp.852~861 (2014)
- Mirza, M. R., "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer", N. Engl. J. Med, 375, pp.2154~2164 (2016)
- Perets, R., "Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models", Cancer Cell, 24, pp.751~765 (2013)
- Zhai, Y., "High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease", J. Pathol, 243, pp.16~25 (2017)
- Konstantinopoulos, P. A., "Homologous Recombination Deficiency : Exploiting the Fundamental Vulnerability of Ovarian Cancer", Cancer Discov, 5, pp.1137~1154 (2015)
- Macintyre, G., "Copy number signatures and mutational processes in ovarian carcinoma", Nat. Genet, 50, pp.1262~1270 (2018)
- Machino, H., "The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma", Commun. Biol, 5, pp.1~15 (2022)
- Dobin, A., "STAR : ultrafast universal RNA-seq aligner", Bioinformatics, 29, pp.15~21 (2013)
- Li, B., "RSEM : accurate transcript quantification from RNA-Seq data with or without a reference genome", BMC Bioinforma, 12, pp.323~ (2011)
- Robinson, M. D., "edgeR : a Bioconductor package for differential expression analysis of digital gene expression data", Bioinformatics, 26, pp.139~140 (2010)
- Nakato, R., "DROMPA : easy-to-handle peak calling and visualization software for the computational analysis and validation of ChIP-seq data", Genes cells : Devoted Mol. Cell. Mechanisms, 18, pp.589~601 (2013)
- Zhang, Y., "Model-based analysis of ChIP-Seq(MACS)", Genome Biol, 9, pp.R137~ (2008)
- Qu, K., "Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors", Cancer Cell, 32, pp.27~41 (2017)
- Hanahan, D., "Hallmarks of cancer: the next generation", Cell, 144, pp.646~674 (2011)
- Buenrostro, J. D., "Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position", Nat. Methods, 10, pp.1213~1218 (2013)
- Khan, A., "JASPAR 2018 : update of the open-access database of transcription factor binding profiles and its web framework", Nucl. Acids Res, 46, pp.D260~D266 (2018)
- Buniello, A., "The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019", Nucl. Acids Res, 47, pp.D1005~D1012 (2019)
- Eferl, R., "AP-1: a double-edged sword in tumorigenesis", Nat. Rev. Cancer, 3, pp.859~868 (2003)
- Morrisey, E. E., "The gene encoding the mitogen-responsive phosphoprotein Dab2 is differentially regulated by GATA-6 and GATA-4 in the visceral endoderm", J. Biol. Chem, 275, pp.19949~19954 (2000)
- Caslini, C., "Histone modifications silence the GATA transcription factor genes in ovarian cancer", Oncogene, 25, pp.5446~5461 (2006)
- Bakiri, L., "Fra-1", AP-1 induces EMT in mammary epithelial cells by modulating Zeb1, Cell Death Differ, pp.2015, 22[DOI]
- Martinelli, P., "GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer", Gut, 66, pp.1665~1676 (2017)
- Serrano-Gomez, S. J., "Regulation of epithelialmesenchymal transition through epigenetic and post-translational modifications", Mol. Cancer, 15, pp.18~ (2016)
- Gourley, C., "WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin 3", Cancer Res, 69, pp.4835~4842 (2009)
- Glover, T. W., "Fragile sites in cancer : more than meets the eye", Nat. Rev. Cancer, 17, pp.489~501 (2017)
- Lopez-Pajares, V., "A LncRNA-MAF : MAFB transcription factor network regulates epidermal differentiation", Dev. Cell, 32, pp.693~706 (2015)
- Communal, L., "A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis", Int J Mol Sci, 22 (2021)[DOI]
- Tripathi, S. C., "Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome", Proc. Natl Acad. Sci. USA, 113, pp.E1555~E1564 (2016)
- Kalaora, S., "Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma", Nat. Commun, 11, pp.896~ (2020)
- Kim, J. Y., "Proteasome inhibition causes epithelial-mesenchymal transition upon TM4SF5 expression", J. Cell Biochem, 112, pp.782~792 (2011)
- Sozen, E., "Potential role of proteasome on c-jun related signaling in hypercholesterolemia induced atherosclerosis", Redox Biol, 2, pp.732~738 (2014)
- Banno, A., "Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition", Oncotarget, 7, pp.21527~21541 (2016)
- Gonzalez, H., "Roles of the immune system in cancer : from tumor initiation to metastatic progression", Genes Dev, 32, pp.1267~1284 (2018)
- Pouponnot, C., "Cell context reveals a dual role for Maf in oncogenesis", Oncogene, 25, pp.1299~1310 (2006)
- Wang, Z., "The mechanism of growth-inhibitory effect of DOC-2", DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2, J. Biol. Chem, pp.2002, 277[DOI]
- Eychene, A., "A new MAFia in cancer", Nat. Rev. Cancer, 8, pp.683~693 (2008)
- Brundage, M. E., "MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1", Oncogene, 33, pp.5626~5636 (2014)
- Hocevar, B. A., "Disabled-2(Dab2)mediates transforming growth factor beta(TGFbeta)-stimulated fibronectin synthesis through TGFbetaactivated kinase 1 and activation of the JNK pathway", J. Biol. Chem, 280, pp.25920~25927 (2005)
- Morozov, A. V., "Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer", Front Oncol, 9, pp.761~ (2019)
- Asakura, T., "Proteasome inhibitorresistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1", Int J. Oncol, 46, pp.2251~2260 (2015)